T cell receptor-engineered T cells (TCR-T) and chimeric antigen receptor T cells (CAR-T) are designed to selectively engage a specific neoantigen presented on major histocompatibility complex (MHC) molecules or a specific tumor-associated antigen (TAA), respectively, on tumor cells [18]. This evidence concerns the gene TBXT and neoplasm.